STOCK TITAN
  1. Home
  2. News
  3. SMMT

Summit Therapeutics Inc. - $SMMT STOCK NEWS

Welcome to our dedicated page for Summit Therapeutics news (Ticker: $SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.

Summit Therapeutics Inc. (SMMT) is a pioneering biopharmaceutical company committed to addressing high unmet medical needs through the discovery, development, and commercialization of novel antibiotics and other therapeutic drugs. Based in the United Kingdom, Summit Therapeutics operates across two primary geographical segments: the United States and the UK.

Summit's research primarily targets Duchenne Muscular Dystrophy (DMD), a fatal genetic muscle wasting disease, and Clostridioides difficile infection (CDI), a serious bacterial infection. Among its leading product candidates is ridinilazole, an orally administered small molecule antibiotic designed to treat CDI. Ridinilazole has shown promising results in clinical trials, positioning it as a potential game-changer in CDI treatment.

The company's strategic focus on these debilitating conditions underscores its commitment to transforming lives through innovative therapeutic solutions. In addition to its drug development programs, Summit Therapeutics has fostered significant partnerships with leading healthcare institutions and biopharmaceutical companies to advance its research and bring new treatments to market efficiently.

Financially, Summit Therapeutics is robust, with a focus on sustainable growth and long-term value creation for its shareholders. The company's dedication to research excellence and patient-centric approach drives its mission to deliver breakthrough therapies that make a meaningful difference in patients' lives.

Stay updated with the latest news and developments from Summit Therapeutics Inc. as the company continues to pioneer advancements in the biopharmaceutical sector, addressing some of the most challenging healthcare needs of our time.

News

Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development

Rhea-AI Summary
Summit Therapeutics Inc. has announced that Dr. Laura Chow has joined the company as Senior Vice President of Clinical Development. Dr. Chow brings two decades of experience in immunotherapy and anti-angiogenic cancer treatment. She has worked on the development of immunotherapies for oncology patients and has extensive experience with major therapies in the field. Dr. Chow's expertise will be valuable in advancing Summit's novel bispecific antibody, ivonescimab, in lung cancer and other solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
clinical trial
-
News

Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

Rhea-AI Summary
Akeso announces that its partner, Summit Therapeutics, will present data for the potential first-in-class bispecific antibody, ivonescimab, at the SITC Annual Meeting. Ivonescimab combines immunotherapy via PD-1 blockade with anti-angiogenesis effects by blocking VEGF. It demonstrates enhanced binding in the presence of both PD-1 and VEGF, potentially targeting tumor tissue. The marketing application for ivonescimab was accepted in China with priority review. Four phase III clinical trials are underway, testing ivonescimab in NSCLC indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
News

Ivonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

Rhea-AI Summary
Summit Therapeutics Inc. announces data for its potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. Ivonescimab combines immunotherapy via a blockade of PD-1 with anti-angiogenesis effects associated with blocking VEGF. It demonstrates enhanced binding in the simultaneous presence of PD-1 and VEGF, with over 18 fold increased binding affinity to PD-1 in the presence of VEGF in vitro. Summit has begun clinical development to establish efficacy and safety in two proposed NSCLC indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
News

Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023

Rhea-AI Summary
Summit Therapeutics Inc. will host an earnings call to announce its third quarter 2023 financial results and provide an operational update for the Company. The call will take place on Tuesday, November 7, 2023, before the market opens. A live webcast will be accessible through Summit’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences earnings
-
News

H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development

Rhea-AI Summary
Dr. Howard West joins Summit Therapeutics as Vice President of Clinical Development focused on lung cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
clinical trial
-
News

Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer

Rhea-AI Summary
Summit Therapeutics announces the appointment of Manmeet S. Soni as Chief Operating Officer and the elevation of Dave Gancarz, Urte Gayko, PhD, Fong Clow, DSc, and Allen S. Yang, MD, PhD to newly established leadership roles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
management
News

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023

Rhea-AI Summary
Promising Phase II data for Ivonescimab presented at ASCO 2023. First US patient treated in Phase III trial, with another trial planned. Collaboration and License Agreement with Akeso for development and commercialization rights. Financially, cash and investments decreased from $654.7M to $215.0M. Net loss for six months ended June 30, 2023 was $557.1M. Operating cash outflow for same period was $42.4M. Earnings call scheduled for August 9, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.86%
Tags
earnings
-
News

Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.7%
Tags
conferences earnings
-
News

Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Ivonescimab Updated Data to be Featured at ASCO 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.91%
Tags
none

FAQ

What does Summit Therapeutics Inc. specialize in?

Summit Therapeutics Inc. specializes in the discovery, development, and commercialization of novel antibiotics for serious infectious diseases.

What are the primary diseases Summit Therapeutics targets?

Summit Therapeutics targets Duchenne Muscular Dystrophy (DMD) and Clostridioides difficile infection (CDI).

What is ridinilazole?

Ridinilazole is an orally administered small molecule antibiotic developed by Summit Therapeutics for treating Clostridioides difficile infection (CDI).

Where does Summit Therapeutics operate?

Summit Therapeutics operates in the United States and the United Kingdom.

What is the company's approach to drug development?

Summit Therapeutics focuses on discovering, developing, and commercializing drugs that address high unmet medical needs, particularly in the areas of DMD and CDI.

Who are Summit Therapeutics' partners?

Summit Therapeutics partners with leading healthcare institutions and biopharmaceutical companies to advance its research and development efforts.

How does Summit Therapeutics ensure sustainable growth?

Summit Therapeutics aims for long-term value creation through a robust financial strategy and a focus on sustainable growth.

What is the significance of Summit Therapeutics' research?

Summit Therapeutics' research aims to develop breakthrough therapies that significantly improve patient outcomes in areas with high unmet medical needs.

How can I stay updated on Summit Therapeutics' developments?

You can stay updated with the latest news and developments from Summit Therapeutics by following their announcements and updates on their official website and financial news platforms.

What is the mission of Summit Therapeutics?

The mission of Summit Therapeutics is to transform lives by delivering innovative therapeutic solutions for serious infectious diseases and other high unmet medical needs.

Stock SMMT logo
Summit Therapeutics Inc.

Nasdaq:SMMT

SMMT Rankings

#1102 Ranked by Market Cap
N/A Ranked by Dividends

SMMT Stock Data

5.89B
82.93M
88.15%
4.91%
3.11%
Biotechnology
Healthcare
Link
United States of America
MENLO PARK